Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial fully enrolled. Non-pharmacological Alzheimer's device targeting FDA clearance.
Cognito Therapeutics is developing a non-pharmacological treatment for Alzheimer's disease using coordinated gamma-frequency light and sound stimulation — a technology called sensory entrainment that modulates neural oscillations implicated in the disease. The company raised an oversubscribed $105 million Series C in March 2026 led by Morningside Ventures, with its pivotal HOPE clinical trial fully enrolled and topline data expected in late 2026.
Raised €11M Series A (Jan 2026). FDA-cleared in 2025. Detects 96%+ of congenital heart defects in prenatal ultrasound. Distributed via GE HealthCare Voluson platform.
BrightHeart is a medical AI company developing prenatal diagnostic tools for detecting congenital heart defects (CHD) — the most common birth defect globally — through standard obstetric ultrasound. The company raised €11 million ($12 million) in Series A financing in January 2026 and achieved five FDA clearances in 2025 ahead of US commercial launch, with distribution through GE HealthCare's Voluson ultrasound platform.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.